Suppression of Polyamine Catabolism by Activated Ki-ras in Human Colon Cancer Cells

Molecular Carcinogenesis

Volumn 39, Issue 2, 2004, Pages 91-102

  Ignatenko, Natalia A ^a   Babbar, Naveen ^a   Mehta, Dipti ^a   Casero Jr , Robert A ^b   Gerner, Eugene W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Colon cancer; Ki ras oncogene; Polyamines; PPAR ; SSAT

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACYLTRANSFERASE; CELL NUCLEUS RECEPTOR; CIGLITAZONE; HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYAMINE; RNA; SPERMIDINE SPERMINE N1 ACETYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CATABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN CACO 2; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE K RAS; POLYAMINE METABOLISM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE;

ACETYLTRANSFERASES; CACO-2 CELLS; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DOWN-REGULATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; POLYAMINES; PROMOTER REGIONS (GENETICS); RAS PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RESPONSE ELEMENTS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0842282485     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10166     Document Type: Article

References (58)

1. Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer 1997;21:233-300.
2. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999;36:801-818.
3. Bos JL. ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689.
4. Font A, Abad A, Monzo M, et al. Prognostic value of Ki-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001;44:549-557.
5. Pruitt K, Der CJ. Ras and Rho regulation of the cell-cycle and oncogenesis. Cancer Lett 2001;171:1-10.
6. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-88.
7. Cohen SS. A guide to the polyamines, vol. xiv. New York: Oxford University Press; 1998. 595 p.
8. Igarashi K, Kashiwagi K. Polyamines: Mysterious modulators of cellular functions. Biochem Biophys Res Commun 2000;271:559-564.
9. Luk GD, Hamilton SR, Yang P, et al. Kinetic changes in mucosal ornithine decarboxylase activity during azoxymethane-induced colonic carcinogenesis in the rat. Cancer Res 1986;46:4449-4452.
10. Hirata K, Itoh H, Nagata N, Kuroda Y, Ohsato K. Experimental carcinogenesis in the rat intestine induced by two different carcinogens-Evaluation of carcinogenic action and its effect on ornithine decarboxylase activity. J Uoeh 1994;16:153-166.
11. Berdinskikh NK, Ignatenko NA, Zaletok SP, Ganina KP, Chorniy VA. Ornithine decarboxylase activity and polyamine content in adenocarcinomas of human stomach and large intestine. Int J Cancer 1991;47:496-498.
12. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986;77:1309-1313.
13. Meyskens FL, Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-951.
14. Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase as a target for chemoprevention. J Cell Biochem Suppl 1995;22:132-138.
15. Casero RA, Jr., Pegg AE. Spermidine/spermine N1-acetyltransferase - The turning point in polyamine metabolism. Faseb J 1993;7:653-661.
16. Fuller DJ, Carper SW, Clay L, Chen JR, Gerner EW. Polyamine regulation of heat-shock-induced spermidine N1-acetyltransferase activity. Biochem J 1990;267:601-605.
17. Gerner EW, Kurtts TA, Fuller DJ, Casero RA, Jr. Stress induction of the spermidine/spermine N1-acetyltransferase by a post-transcriptional mechanism in mammalian cells. Biochem J 1993;294:491-495.
18. Chopra S, Wallace HM. Induction of spermidine/spermine N1-acetyltransferase in human cancer cells in response to increased production of reactive oxygen species. Biochem Pharmacol 1998;55:1119-1123.
19. Seiler N. Functions of polyamine acetylation. Can J Physiol Pharmacol 1987;65:2024-2035.
20. Xie X, Gillies RJ, Gerner EW. Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates. J Biol Chem 1997;272:20484-20489.
21. Turchanowa L, Dauletbaev N, Milovic V, Stein J. Nonsteroidal anti-inflammatory drugs stimulate spermidine/spermine acetyltransferase and deplete polyamine content in colon cancer cells. Eur J Clin Invest 2001;31:887-893.
22. Casero RA, Jr., Celano P, Ervin SJ, Porter CW, Bergeron RJ, Libby PR. Differential induction of spermidine/spermine N1-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues. Cancer Res 1989;49:3829-3833.
23. Porter CW, Ganis B, Libby PR, Bergeron RJ. Correlations between polyamine analogue-induced increases in spermidine/spermine N1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res 1991;51:3715-3720.
24. Porter CW, Bernacki RJ, Miller J, Bergeron RJ. Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. Cancer Res 1993;53:581-586.
25. Hahm HA, Ettinger DS, Bowling K, et al. Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer. Clin Cancer Res 2002;8:684-690.
26. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-812.
27. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-424.
28. Vanden Heuvel JP. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol Sci 1999;47:1-8.
29. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275-13280.
30. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345.
31. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate Ki-ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002;62:3282-3288.
32. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 1996;222:844-851.
33. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun 2000;272:380-385.
34. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPAR-gamma gene. J Biol Chem 1997;272:18779-18789.
35. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
36. Holtta E, Sistonen L, Alitalo K. The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells. J Biol Chem 1988;263:4500-4507.
37. Shantz LM, Pegg AE. Ornithine decarboxylase induction in transformation by H-Ras and RhoA. Cancer Res 1998;58:2748-2753.
38. Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW. Influence of Ki-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 2000;9:1155-1162.
39. Taylor MT, Lawson KR, Ignatenko NA, et al. Sulindac sulfone inhibits Ki-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res 2000;60:6607-6610.
40. Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB. Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal, and gastric cancer. Oncogene 1989;4:923-928.
41. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: Doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 2001;299:434-441.
42. Xiao L, Celano P, Mank AR, et al. Structure of the human spermidine/spermine N1-acetyltransferase gene (exon/intron gene organization and localization to Xp22.1). Biochem Biophys Res Commun 1992;187:1493-1502.
43. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
44. Ignatenko NA, Gerner EW. Growth arrest- and polyamine-dependent expression of spermidine/spermine N1-acetyltransferase in human tumor cells. Cell Growth Differ 1996;7:481-486.
45. Seiler N, Knodgen B. High-performance liquid chromatography procedure for the simultaneous determination of the natural polyamines and their monoacetylderivatives. J Chromatogr 1980;221:227-238.
46. Singh J, Kulkarni N, Kelloff G, Reddy BS. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 1994;15:1317-1323.
47. Ignatenko NA, Fish JL, Shassetz LR, Woolridge DP, Gerner EW. Expression of the human spermidine/spermine N1-acetyltransferase in spermidine acetylation-deficient Escherichia coli. Biochem J 1996;319:435-440.
48. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-1413.
49. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-970.
50. Wu Z, Xie Y, Bucher NL, Farmer SR. Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Genes Dev 1995;9:2350-2363.
51. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-819.
52. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.
53. Komura J, Okada T, Ono T. Repression of transient expression by DNA methylation in transcribed regions of reporter genes introduced into cultured human cells. Biochim Biophys Acta 1995;1260:73-78.
54. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999;3:799-804.
55. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998;4:1058-1061.
56. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053-1057.
57. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996;274:2100-2103.
58. Camp HS, Tafuri SR. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 1997;272:10811-10816.